SEC Form 4 · accession 0001567619-19-006485
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Leslie Sloan
Officer — Chief Operating Officer
Period of report
Mar 6, 2019
Accepted (ET)
Mar 8, 2019 · 4:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636282
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $8.06 | Mar 6, 2019 | A | 36,000 | A | — | Mar 5, 2029 | Common Stock | 36,000 | 36,000 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable in 48 equal monthly installments beginning on April 6, 2019, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.